Treatment alternatives for multidrug-resistant fungal pathogens
Drug Discovery Today, ISSN: 1359-6446, Vol: 28, Issue: 6, Page: 103596
2023
- 3Citations
- 8Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Review Description
Several fungal pathogens are becoming resistant to conventional fungal infection treatments, and some fungal pathogens have become multidrug-resistant. Alternative treatments include fungal vaccines, conventional or synthetic monoclonal antibody (mAb) injections, or potentially conventional or synthetic mAbs produced in vivo by injections of appropriately packaged mRNA. Specifically synthesized proteins can mask distinctive pathogenic fungal surface proteins and target pathogenic fungal proteins to stop fungal infections. Treatments could also use combinations of one or more antifungal drugs combined with direct injections or injections of packaged mRNA with instructions for patient synthesis of either the conventional or synthetic mAbs. These alternative treatments offer potentially significant advantages compared with existing treatments for fungal pathogens.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1359644623001125; http://dx.doi.org/10.1016/j.drudis.2023.103596; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85153942228&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/37086779; https://linkinghub.elsevier.com/retrieve/pii/S1359644623001125; https://dx.doi.org/10.1016/j.drudis.2023.103596
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know